Oncology Diagnostics for Precision Medicine

Clinically validated, pathology and integrated oncology diagnostics to support confident treatment decisions

Oncology care is increasingly driven by precision diagnostics. As treatment strategies become more targeted and biomarker-dependent, the accuracy, sensitivity, and integration of diagnostic testing play a critical role in guiding clinical decisions.

At Parkway Laboratory Services, our oncology diagnostics are anchored in high-end pathology expertise, precision-driven technologies, and integrated laboratory workflows. We support clinicians with clinically validated diagnostic testing that enables accurate disease characterisation, therapy selection, and comprehensive oncology assessment, all within a single trusted laboratory partner.

Pathology Techniques at the Core of Precision Oncology

Precision oncology begins with diagnostic accuracy at the tissue and cellular level. Parkway Laboratory Services places pathology techniques at the centre of our oncology diagnostics, ensuring high analytical sensitivity and clinical relevance.

Our oncology diagnostics are built on:

• Specialised immunohistochemistry (IHC) and in situ hybridisation (ISH) platforms
• High-sensitivity assays for biomarker detection and disease characterisation
• Pathologist-led interpretation, ensuring results are clinically meaningful
• Robust quality and governance frameworks supporting diagnostic confidence

These capabilities allow clinicians to move beyond conventional testing and access deeper biological insights that support precision treatment strategies.

Key Oncology Diagnostic Offerings

Kappa and Lambda in situ hybridisation (ISH) provides a highly sensitive method for detecting plasma cell clonality in bone marrow and tissue biopsies. Compared to traditional immunohistochemistry, ISH offers improved sensitivity and specificity, particularly in challenging or low-burden cases.

Why it matters:

• More accurate assessment of monoclonality
• Improved diagnostic confidence in plasma cell disorders
• Supports the diagnosis and evaluation of multiple myeloma and related conditions

Parkway Laboratories is among the few clinical laboratories locally offering combined Kappa and Lambda ISH testing as part of routine diagnostic evaluation.

FOLR1 IHC - Companion diagnostic testing for targeted ovarian cancer therapy

Folate Receptor Alpha (FOLR1) immunohistochemistry is a companion diagnostic used to identify patients with FOLR1-positive, platinum-resistant ovarian cancer who may benefit from targeted therapy.

Parkway Laboratories is among the first clinical laboratories to offer validated FOLR1 IHC testing aligned with approved targeted treatment pathways.

Why it matters:

• Aligns therapy selection with tumour biology
• Reduces trial-and-error treatment approaches
• Supports personalised treatment decisions in ovarian cancer care

Gastric Cancer IHC Bundle - Integrated biomarker profiling for gastric and GEJ adenocarcinoma

Comprehensive biomarker profiling has become essential in gastric and gastroesophageal junction (GEJ) adenocarcinoma, particularly in HER2-negative disease. An integrated diagnostic approach enables timely and precise treatment decisions.

Our gastric cancer IHC bundles include the following:

Claudin 18.2 is offered as a companion diagnostic following regulatory approval of targeted therapy, supporting precision treatment planning in eligible patients.

Why it matters:

• Comprehensive biomarker evaluation in a single workflow
• Supports therapy selection beyond HER2 status
• Reduces diagnostic fragmentation and turnaround time

Integrated Oncology Diagnostics — One Trusted Laboratory Partner

Beyond individual tests, Parkway Laboratories offers integrated oncology diagnostics that reduce complexity for clinicians and healthcare teams.

Our integrated approach means:

• Multiple oncology biomarkers assessed within a single laboratory system
• Fewer handoffs between laboratories
• Consistent quality, interpretation, and reporting
• Streamlined workflows supporting timely clinical decisions

By combining pathology techniques with integrated diagnostic workflows, we enable clinicians to focus on patient care, without the operational burden of coordinating multiple laboratory providers.